Emergent

History

Year	Detail
1998	El-Hibri founded Emergent (then BioPort).
2003	The company acquired the first Maryland-based site in Gaithersburg.
2009	The company acquired a manufacturing facility in Baltimore's neighborhood.
2014	Emergent acquired Cangene Corp. for an aggregate purchase price of $222 million, expanding the growing biodefense market.
2017	The company acquired the smallpox (Vaccinia) Vaccine, Live) business ACAM2000, from Sanofi, and Raxibacumab, a fully human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax, from GSK.
2018	The company acquired Adapt Pharma and its product, NARCAN.
2022	The company acquired TEMBEXA, an oral antiviral vaccine for the treatment of smallpox, from Chimerix. It further collaborated with Ridgeback Therapeutics on Ebanga Treatment for Ebola.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.